Medtronic Earnings Reports

Medtronic reported revenue growth of 2.5% YoY, with strong performance in Pulsed Field Ablation, Neuromodulation, and Diabetes. Adjusted EPS grew 7% YoY, driven by operating margin expansion. The company reiterated its full-year guidance.

Medtronic reported a strong second quarter in fiscal year 2025, with revenue of $8.4 billion, a 5.3% increase as reported and 5.0% organic. GAAP diluted EPS was $0.99, while non-GAAP diluted EPS reached $1.26. The company has raised its full-year guidance for both organic revenue growth and EPS.

Medtronic reported Q1 worldwide revenue of $7.915 billion, an increase of 2.8% as reported and 5.3% on an organic basis. GAAP diluted earnings per share (EPS) were $0.80; non-GAAP diluted EPS of $1.23. The company raised its FY25 organic revenue growth guidance to 4.5% to 5% and diluted non-GAAP EPS guidance to the new range of $5.42 to $5.50.

Medtronic reported Q4 worldwide revenue of $8.589 billion, a 0.5% increase as reported and a 5.4% increase on an organic basis. GAAP diluted EPS was $0.49, while non-GAAP diluted EPS was $1.46. The company's organic revenue results reflect broad-based growth across the company, with mid-single digit or higher organic revenue growth in all four segments.

Medtronic reported a 4.7% increase in revenue to $8.1 billion, with organic revenue growth of 4.6%. GAAP EPS was $0.99, and non-GAAP EPS was $1.30. The company raised its full-year organic revenue growth and EPS guidance.

Medtronic reported a solid Q2 2024 with revenue of $8.0 billion, a 5.3% increase as reported and 5.0% organically. GAAP EPS was $0.68, and non-GAAP EPS was $1.25. The company raised its FY24 organic revenue growth and EPS guidance.

Medtronic reported a solid start to fiscal year 2024, with revenue of $7.7 billion, a 4.5% increase as reported and 6.0% organic. GAAP EPS was $0.59, a 16% decrease, while non-GAAP EPS was $1.20, a 6% increase. The company has raised its FY24 organic revenue growth and EPS guidance.

Medtronic reported a strong finish to fiscal year 2023, with Q4 revenue of $8.5 billion, a 5.6% increase as reported and organic. GAAP diluted EPS was $0.88, a 20% decrease, while non-GAAP diluted EPS was $1.57, a 3% increase. The company issued FY24 guidance, projecting organic revenue growth in the range of 4.0% to 4.5% and non-GAAP EPS in the range of $5.00 to $5.10.

Medtronic's Q3 2023 revenue reached $7.7 billion, remaining flat as reported but increasing by 4.1% organically, surpassing expectations. GAAP diluted EPS was $0.92, a 16% decrease, while non-GAAP diluted EPS was $1.30, a 4% decrease, also exceeding expectations. The company has raised its FY23 organic revenue growth and EPS outlook.

Medtronic reported a 3% decrease in revenue, totaling $7.6 billion, but experienced a 2% increase on an organic basis. GAAP diluted EPS decreased by 67% to $0.32, while non-GAAP diluted EPS decreased by 2% to $1.30. The company has updated its guidance and anticipates organic revenue growth to accelerate in the second half of the fiscal year.

Medtronic's Q1 2023 revenue reached $7.371 billion, a decrease of 8% as reported and 4% organically. GAAP diluted EPS increased by 25% to $0.70, while non-GAAP diluted EPS decreased by 17% to $1.13. The company reiterated its FY23 revenue and EPS guidance.

Medtronic reported a 1% decrease in Q4 revenue to $8.1 billion, but a 1% increase on an organic basis. GAAP diluted EPS increased by 10% to $1.10, while non-GAAP diluted EPS increased by 2% to $1.52. The company issued FY23 guidance, expecting organic revenue growth of 4% to 5% and non-GAAP EPS in the range of $5.53 to $5.65.

Medtronic reported flat revenue year-over-year at $7.8 billion, with 2% organic growth. GAAP diluted EPS grew 17% to $1.10, while non-GAAP diluted EPS increased 6% to $1.37. The company issued Q4 revenue and EPS guidance, expecting healthcare procedures to reaccelerate post-Omicron.

Medtronic reported a 3% increase in revenue to $7.8 billion, with organic revenue growth of 2%. GAAP diluted EPS increased by 169% to $0.97, while non-GAAP diluted EPS increased by 29% to $1.32. The company is reiterating its full year EPS guidance.

Medtronic reported a strong start to fiscal year 2022, with Q1 revenue of $8.0 billion, a 23% increase as reported and 19% on an organic basis. GAAP diluted EPS was $0.56, while non-GAAP diluted EPS was $1.41. The company reiterated its FY22 revenue guidance and raised the lower end of its EPS guidance.

Medtronic reported a strong end to fiscal year 2021, with fourth quarter revenue of $8.188 billion, a 37% increase as reported and 32% organically. GAAP diluted EPS was $1.00, and non-GAAP diluted EPS was $1.50. The company announced a 9% dividend increase and issued FY22 guidance.

Medtronic reported a Q3 revenue of $7.775 billion, a 0.8% increase as reported, but a 1.0% decrease organically. The GAAP diluted EPS was $0.94, while the non-GAAP diluted EPS was $1.29, both decreasing by 10%. The company's performance was impacted by the resurgence of COVID-19, which affected procedure volumes.

Medtronic reported a decrease in revenue by 0.8% to $7.6 billion. The GAAP diluted EPS was $0.36, and the non-GAAP diluted EPS was $1.02.

Medtronic reported a 13% decrease in Q1 revenue to $6.507 billion, with a GAAP diluted EPS of $0.36 and a non-GAAP diluted EPS of $0.62. The results were impacted by the COVID-19 pandemic, but the company saw a faster than expected recovery with improving procedure volumes.

Medtronic reported a 26% decrease in Q4 revenue to $6.0 billion, with GAAP EPS at $0.48 and non-GAAP EPS at $0.58. The results were in line with previous updates, reflecting the impact of deferred procedures due to the COVID-19 pandemic. Despite the challenges, the company increased its dividend, showcasing its financial strength.

Medtronic reported a 2.3% increase in revenue to $7.7 billion and a 51% increase in GAAP diluted EPS to $1.42. The company also raised its full-year EPS guidance.